Study title: Wirksamkeit, Sicherheit und Verträglichkeit von Norgestimat-CIL (Cilest) zur hormonalen Empfängnisverhütung unter besonderer Berücksichtigung der gewichtsbezogenen Abhängigkeit der Verträglichkeit. Offene multizentrische Breiteprüfung.14-49 Jahre Studiendauer: 01.1991-12.1992
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Endocrine System Diseases [C19] | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: Ethinylestradiol + Norgestimate | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |